Patients with familial atypical multiple mole melanoma (FAMMM), a hereditary cancer syndrome caused by mutation of cyclin‐dependent kinase inhibitor 2A (CDKN2A), are known to have a significantly higher risk of melanoma and pancreatic cancer.3 This evidence concerns the gene CDKN2A and melanoma.